CliffBio
small molecule

NIFEDIPINE

NIFEDIPINE

Loss of exclusivity—loss of exclusivity
CompanyOsmotica Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameNIFEDIPINE
Active ingredientNIFEDIPINE
Strength30MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2005
Marketing statusRX

More from Osmotica Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NIFEDIPINE patent cliff — loss of exclusivity — | CliffBio